BDTX
Black Diamond·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 4
Bearish signal 1
Consensus Rating "Strong Buy"
Ample Liquidity
High Gross Profit Margin
RSI Oversold
EPS Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About BDTX
Black Diamond Therapeutics, Inc.
A company that developing small molecule, tumor-agnostic therapies for cancers
Biological Technology
--
01/30/2020
NASDAQ Stock Exchange
24
12-31
Common stock
One Main Street, 14th Floor, Cambridge, Massachusetts 02142
--
Black Diamond Therapeutics, Inc., was incorporated in Delaware in December 2014. The company is a clinical-stage oncology company focused on developing MasterKey therapies for the treatment of patients with genetically defined tumors. The company's goal is to genetically define cancer-causing driver mutations in cancer patients where drugs do not exist.
Company Financials
EPS
BDTX has released its 2025 Q3 earnings. EPS was reported at -0.15, versus the expected -0.23, beating expectations. The chart below visualizes how BDTX has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
